Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.

  title={Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes.},
  author={Sylvia H. Jackson and Tonya S Martin and Jocelyn D. Jones and David Seal and Frank S. Emanuel},
  journal={P & T : a peer-reviewed journal for formulary management},
  volume={35 9},
498 P&T® • September 2010 • Vol. 35 No. 9 INTRODUCTION According to the Centers for Disease Control and Prevention (CDC) prevalence data for 2007, diabetes is a chronic and progressive disease that af fects nearly 24 million people in the U.S.1 It is projected that by the year 2030, more than 30 million people will have diabetes.2 From 90% to 95% of diagnosed cases are type-2 diabetes, which is characterized by insulin resistance and an altered secretion of pancreatic beta cells, leading to… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
2 Extracted Citations
28 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 28 references

Available at www.mckesson

  • McKesson Corp, San Francisco
  • com. Accessed June
  • 2010

U.S. approval for Victoza (liraglutide) for the treatment of type 2 diabetes

  • Novo Nordisk
  • January 26,
  • 2010

Lira glutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 MONO): Randomized, 52-week, phase III, doubleblind, parallel-treatment trial

  • A Garber, R Henry, R Ratner
  • Lancet
  • 2009

Similar Papers

Loading similar papers…